SLC25A38: A Potential Drug Target and Biomarker (G54977)

Target Name: SLC25A38

NCBI ID: G54977

SLC25A38

SLC25A38: A Potential Drug Target and Biomarker

Solute Carrier Family 25 (SCF25) is a family of transmembrane proteins that play a crucial role in intracellular signaling and transport. The SCF25 family consists of four subfamilies, including SCF25A, SCF25B, SCF25C, and SCF25D. The focus of this article is on SCF25A38, a protein that has potential as a drug target or biomarker.

SCF25A38 is a 38kDa protein that is expressed in various tissues, including brain, heart, and skeletal muscles. It is a member of the SCF25A subfamily and has been identified as a potential drug target due to its unique structure and biology.

The SCF25A38 protein is involved in the intracellular transport of various molecules, including neurotransmitters, hormones, and ions. It is a transmembrane protein that consists of an N-terminal cytoplasmic domain, a transmembrane segment, and an C-terminal cytoplasmic domain. The cytoplasmic domain is responsible for the protein's ability to interact with intracellular signaling molecules, while the transmembrane segment is responsible for its ability to transport molecules across the membrane.

One of the key features of SCF25A38 is its unique structure. Unlike many other proteins, SCF25A38 does not contain a well-defined N-terminus or C-terminus. Instead, it has a long, extracellular N-terminal region that is involved in protein-protein interactions and may function as a scaffold to promote protein-protein interactions in the cell. Additionally, SCF25A38 has a unique C-terminus that is involved in the formation of a dimeric complex with other proteins, including the protein Pyknotide. This dimerization event is thought to play a role in regulating the activity of SCF25A38 and may be a potential target for drugs that target this process.

In addition to its unique structure, SCF25A38 has been shown to play a role in various cellular processes. For example, it has been shown to be involved in the regulation of neurotransmitter release from dopamine-producing neurons in the brain. Additionally, SCF25A38 has been shown to play a role in the regulation of ion transport in muscle fibers.

As a potential drug target, SCF25A38 offers several advantages as a target for small molecule inhibitors. First, it has a unique structure that makes it more difficult to predict its function and develop targeted inhibitors. Second, its role in various cellular processes makes it more difficult to predict its function and develop targeted inhibitors. Finally, its unique C-terminus and dimerization event make it more difficult to predict its function and develop targeted inhibitors.

In conclusion, SCF25A38 is a unique protein that has potential as a drug target or biomarker. Its unique structure and biology make it difficult to predict its function and develop targeted inhibitors. Further research is needed to fully understand the role of SCF25A38 in cellular processes and its potential as a drug target.

Protein Name: Solute Carrier Family 25 Member 38

Functions: Mitochondrial glycine transporter that imports glycine into the mitochondrial matrix. Plays an important role in providing glycine for the first enzymatic step in heme biosynthesis, the condensation of glycine with succinyl-CoA to produce 5-aminolevulinate (ALA) in the mitochondrial matrix. Required during erythropoiesis

The "SLC25A38 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A38 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets